Recap: Intellia Therapeutics Q1 Earnings

Shares of Intellia Therapeutics NTLA were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 28.57% over the past year to ($0.63), which missed the estimate of ($0.44).

Revenue of $12,916,000 higher by 23.80% year over year, which missed the estimate of $18,140,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Intellia Therapeutics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 07, 2020

Time: 09:05 AM ET

Webcast URL: https://ir.intelliatx.com/events/event-details/intellia-therapeutics-first-quarter-2020-earnings-conference-call

Recent Stock Performance

52-week high: $19.00

52-week low: $9.18

Price action over last quarter: Up 7.12%

Company Description

Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.